Loading
Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.
Qing Zhou led HARMONi-2, the first randomised trial in which a new agent (ivonescimab, a PD-1 and VEGF bispecific antibody) beat pembrolizumab on progression-free survival in PD-L1-positive NSCLC, and HARMONi-A in EGFR-mutant disease after TKI failure. She works alongside Yi-Long Wu at the Guangdong Lung Cancer Institute and leads CTONG trials.
| Title | Journal | Year |
|---|---|---|
| Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2) | Lancet | 2025 |
| Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant (HARMONi-A) | JAMA | 2024 |
| HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer | The Lancet | 2025 |
Shares HARMONi-2, Ivonescimab, VEGF / VEGFR, Bispecific antibodies and the tag china.
Shares HARMONi-2, Ivonescimab and the tag china.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares Guangdong Provincial People's Hospital, Non-small-cell lung cancer and the tag china.
Shares HARMONi-2, HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer, Ivonescimab, VEGF / VEGFR.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares Non-small-cell lung cancer and the tag china.